# Hesitation of People Regarding Cervical Cancer Vaccine

**Arfa Eeman**

1ST Year MBBS, Islamabad Medical and Dental College, Islamabad, Pakistan

***Key points:***

- Cervical cancer
- HPV vaccine
- Vaccine hesitancy
- Public health
- Awareness

## Introduction

Cervical cancer remains a major public health concern, particularly in low- and middle-income countries. It is primarily caused by persistent infection with high-risk types of human papillomavirus (HPV). Despite the proven efficacy and safety of HPV vaccines, hesitancy toward vaccination continues to limit coverage and impact. Understanding the factors contributing to this hesitation is essential for improving vaccine uptake and reducing disease burden[1].

## Burden of Cervical Cancer

Cervical cancer is the fourth most common cancer among women globally, with a disproportionately higher incidence and mortality in developing regions.

Limited access to screening and preventive services inevitably accelerates this burden. HPV vaccination offers a highly effective primary prevention strategy, capable of preventing up to 90% of cervical cancer cases when administered appropriately[2].

## Concept of Vaccine Hesitancy

Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services. It is influenced by factors such as confidence, complacency, and convenience. In the context of HPV vaccination, hesitancy is particularly pronounced due to sociocultural and informational barriers[3].

## Factors Contributing to Hesitation

1. Lack of Awareness and Knowledge

Many individuals have limited awareness about HPV, its transmission, and its link to cervical cancer. Furthermore, misconceptions regarding the necessity and benefits of the vaccine significantly reduce acceptance rates[4].

2. Safety Concerns and Misinformation

Concerns about vaccine safety, side effects, and long-term health impacts are common. The spread of misinformation through social media and informal networks further amplifies fear and distrust[5].

3. Cultural and Religious Beliefs

In some societies, HPV vaccination is incorrectly associated with promoting sexual activity, leading to resistance from parents and communities. Cultural taboos surrounding discussions of sexual health also hinder awareness[6].

4. Gender and Social Norms

HPV vaccination programs often target adolescent girls, which may create gender-specific stigma. In some settings, male involvement in vaccination decisions is limited, affecting uptake[7].

5. Accessibility and Cost Issues

Limited availability, high cost, and inadequate healthcare infrastructure contribute to low vaccination rates, particularly in rural and underserved areas[8].

**Strategies to Overcome Hesitation**

1. Public Education Campaigns

Awareness programs focusing on the safety, efficacy, and importance of HPV vaccination can improve acceptance. Educational interventions should be culturally sensitive and evidence-based[9].

2. Healthcare Provider Recommendation

Strong recommendations from healthcare professionals significantly influence vaccination decisions. Training providers to communicate effectively can enhance trust[10].

3. Policy and Government Initiatives

Inclusion of HPV vaccine in national immunization programs and provision of free or subsidized vaccines can improve coverage[11].

4. Community Engagement

Involving community leaders, educators, and parents in awareness campaigns can help address sociocultural barriers and build trust[12].

**Conclusion**

Hesitation regarding cervical cancer vaccination is a multifactorial issue influenced by knowledge gaps, cultural beliefs, safety concerns, and accessibility barriers. Addressing these factors through targeted education, policy support, and community engagement is essential to improve vaccine uptake. Strengthening public confidence in HPV vaccination will play a crucial role in reducing the global burden of cervical cancer.

**References**


1. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization; 2020 Dec 31.
2. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The lancet global health. 2023 Feb 1;11(2):e197-206.
3. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015 Aug 14;33(34):4161-4.
4. Heyde S, Osmani V, Schauberger G, Cooney C, Klug SJ. Global parental acceptance, attitudes, and knowledge regarding human papillomavirus vaccinations for their children: a systematic literature review and meta-analysis. BMC Women's Health. 2024 Sep 27;24(1):537.
5. Zappullo I, Catalano L, De Biase R, Panico F, D'Olimpio F, Sagliano L, Trojano L. Tailoring educational interventions targeting parental vaccine hesitancy: a systematic review of quantitative studies. Frontiers in Public Health. 2026 Apr 7;14:1793920.
6. Noreen K, Khalid SN, Javaid M, Khan SA. Public Health Implications of Introducing Human Papillomavirus (HPV) Vaccination in Pakistan: A protocol for a mixed-method study to explore community perceptions and health system preparedness. Plos One. 2025 May 22;20(5):e0323826.
7. White JL, Grabowski MK, Rositch AF, Gravitt PE, Quinn TC, Tobian AA, Patel EU. Trends in adolescent human papillomavirus vaccination and parental hesitancy in the United States. The Journal of infectious diseases. 2023 Sep 1;228(5):615-26.

8. Serrano B, Castellsagué X, Brotons M, Muñoz J, Bruni L, Bosch FX. Human papillomavirus (HPV) and related cancers in the global Alliance for vaccines and immunization (GAVI) countries: A WHO/ICO HPV information Centre report. de Sanjosé S, editor. Elsevier; 2012 Nov 20.
9. Perkins RB, Legler A, Jansen E, Bernstein J, Pierre-Joseph N, Eun TJ, Biancarelli DL, Schuch TJ, Leschly K, Fenton AT, Adams WG. Improving HPV vaccination rates: a stepped-wedge randomized trial. Pediatrics. 2020 Jul 1;146(1):e20192737.
10. Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine. 2016 Feb 24;34(9):1187-92.
11. Mansilla C, Kamlongera A, Dadari I. Gender Barriers to Immunization: A Synthesis of UNICEF's Analyses to Advance Equity and Coverage. Vaccines. 2025 Oct 16;13(10):1059.
12. Larson HJ. The state of vaccine confidence. The Lancet. 2018 Nov 24;392(10161):2244-6.
13. Acharya S. HPV vaccination and cervical cancer: A global picture | figo [Internet]. 2021 [cited 2026 Jul 19]. Available from: https://www.figo.org/news/hpv-vaccination-and-cervical-cancer-global-picture